Approved, but not adopted
Approval created the right to sell, not the pull to adopt. Funded use is still lagging.
Commercialization Execution for Regulated Health
From Approval to Adoption and Growth
We help regulated health companies accelerate launch, market entry, and revenue execution in Canada and the U.S.
Problems We Solve
The commercial problems most often slowing growth
The issues most often slowing launch, adoption, and market entry.
Procurement is slow and reimbursement is not lined up
The product is stuck in review, coding, budget cycles, or access logic that was underestimated.
The field team is busy, but growth is flat
Activity is high, but growth is flat because targeting, sequencing, sales motion, or field capability is off.
Canada and the U.S. are being treated like the same market
Canada and the U.S. require different payer, access, procurement, and adoption strategies.
The pilot created activity, not scale
The pilot created interest, but not a credible path to procurement, scale, or repeatability.
AI is being discussed, but not operationalized
AI is being discussed, but governance, rollout discipline, and measurable value are still unclear.
How We Help
How Strategic Growth AI helps move the work forward
Diagnostic
Commercialization diagnostics
Clarify what is slowing commercialization and what needs to change first.
Access
Market access and institutional pathway execution
Move the work between approval and uptake, from reimbursement logic to institutional sequencing.
Scale
Pilot-to-procurement redesign
Redesign pilots around workflow fit, stakeholder logic, evidence needs, and scale criteria.
Cross-Border
Canada-U.S. commercialization
Build the right Canada-U.S. sequence for payer, access, procurement, and institutional realities.
Field
Field execution and commercial reset
Sharpen targeting, account strategy, territory cadence, and field execution when traction is weak.
AI
AI workflow enablement for regulated environments
Identify practical AI use cases, then build the governance and rollout structure to implement them.
Engagement Model
Three ways companies bring us in
Focused commercial diagnostic
For a specific commercial problem that needs fast clarity.
- Launch drag
- Market access delays
- Pilot failure
- Weak field traction
Embedded execution leadership
For companies that need senior commercial capacity inside active workstreams.
- Launch execution
- Cross-functional accountability
- Institutional progress
- Commercial discipline
Build-operate-transfer
For companies entering new markets or building capability they do not yet have.
- Cross-border entry
- Capability build
- Operator-led execution
- Transfer back to the team
Selected Outcomes
Successful engagements
Rare Disease
Rare disease launch buildout
Built the Canadian commercial path for a dormant rare disease treatment, including launch setup, patient support, and access execution.
Launch buildAccess executionPatient support
Digital Health
Digital health scale and exit support
Repositioned a digital health platform around credibility, KOL demand, and adoption pathways that supported growth and exit readiness.
Scale supportKOL demandExit readiness
Diagnostics
Diagnostics market disruption
Helped a challenger diagnostics lab break into an entrenched market, activate 1,700+ sites, and build credibility at scale.
Market disruption1,700+ sitesCredibility at scale
Why Strategic Growth AI
Execution With Accountability
We combine strategy with operating accountability so decisions turn into commercial movement.
| What you need | Traditional consulting | SGAI |
|---|---|---|
| Focused starting point | ✕ Broad advisory menu | ✓ Diagnostics and targeted review engagements |
| Execution ownership | ✕ Advice without accountability | ✓ Milestone-based execution support |
| Pilot, to, scale capability | ✕ Pilot design in isolation | ✓ Pilot design linked to adoption and scale |
| AI workflow support | ✕ Generic transformation language | ✓ Regulated workflow enablement |
| Commercial accountability | ✕ Deliverable, based | ✓ Outcome, oriented |
FAQ
Questions Clients Ask
In most cases, the right starting point is your most immediate commercialization priority, launch readiness, pilot performance, market access, market entry, or workflow execution.
Execution is central to our model. We support planning, milestone management, stakeholder sequencing, market access, pilot redesign, commercialization PMO, contracting, field execution, and embedded commercialization office support.
No. Our focus is AI workflow enablement for regulated teams: use, case selection, workflow design, governance, human oversight, rollout support, and ROI tracking.
Yes. Our operating footprint covers Canada and the United States, with particular strength in regulated markets where payer logic, institutional adoption, reimbursement, and commercialization sequencing directly impact revenue timing.
Next step
Discuss a Live Commercial Priority
Use the form below to discuss a launch, access, pilot, market entry, field execution, or AI workflow priority.
Specialty Pharma · Biotech · Diagnostics · Medtech · AI Health
Commercial Model
Diagnose the Constraint. Move the Work Forward.
This page brings the real commercial constraint and the execution response together. The objective is not more activity. It is to identify what is actually slowing growth, then apply the operating model required to change revenue timing, adoption, contracting, and scale.
Interactive Diagnostic
Choose the constraint that looks most like your current reality
Each card shows how Strategic Growth AI responds when the issue is access, sequencing, conversion, team capability, or market-entry discipline.
Strategic Hunter Trajectory
From stalled activity to measurable commercial movement
Teams often get stuck between approval, pilot, procurement, and scaled use. We focus on the real decision path that moves adoption and revenue.
Turn around stagnant commercial pipelines and re-focus the work on the accounts, buyers, and proof points that can move revenue.
Execute institutional sales across hospitals, IDNs, health systems, and payer-shaped buying environments.
Support Canada and United States market entry where reimbursement logic, institutional adoption, and local networks determine timing.
Illustrative trajectory: typical status quo versus Strategic Growth AI execution support.
Capability Areas
Where we deploy when the work has to move
These are execution-heavy capabilities built to unblock revenue, compress timelines, and install a repeatable commercial model.
Launch and Scale
Turn regulatory progress into uptake through launch sequencing, account activation, and adoption logic.
Institutional Sales Execution
Map the buying committee, align clinical and economic stakeholders, and move complex contracting forward.
Revenue Turnaround
Fix stalled pipelines, reset field execution, and build the cadence needed to convert activity into business.
Cross-Border Enablement
Support Canada-U.S. expansion with the right reimbursement, sequencing, workflow, and local execution model.
Services
Commercialization Services
Strategic Growth AI delivers focused commercialization support for regulated health companies seeking sharper strategic decisions, disciplined execution, and measurable commercial progress.
Commercial Strategy
Evaluate your commercialization pathway, identify where value may stall, and clarify the strategic decisions your leadership team must make next.
- Commercialization diagnostic
- Launch readiness review
- Scenario modeling and downside review
- Board and leadership decision support
Market Access and Evidence
Align payer, HTA, clinical, and commercial requirements before resources are committed to work that will not support funded adoption.
- Reimbursement pathway mapping
- Evidence package prioritization
- Stakeholder and formulary sequencing
- Commercial evidence planning
Pilot to Scale
Design or reset pilots around adoption logic, procurement relevance, evidence generation, and scale criteria.
- Pilot design or reset
- Success metrics tied to adoption
- Stakeholder and account sequencing
- Post, pilot scale plan
AI Workflow Enablement
Support AI adoption where commercial and regulatory workflows have clear friction, while keeping scope disciplined, governed, and practical.
- Use, case selection and prioritization
- Workflow architecture and HITL design
- Governance and decision rights
- Rollout and ROI tracking
Embedded Commercial Leadership
Add senior commercialization capability without waiting for a full internal build. Embed, operate, and transfer capability as the organization matures.
- Fractional commercial leadership
- Launch PMO and milestone ownership
- Commercial operating cadence
- Build, operate, transfer support
Launch and Institutional Support
Support the work that turns plans into traction, including institutional sequencing, contracting, field enablement, and account activation.
- Launch sequencing and follow, through
- Institutional contracting support
- Field enablement and deployment
- Account activation planning
Go, to, Market and Market Entry
Support Canada and United States expansion where regulatory, payer, institutional, and commercial pathways need to align.
- Canada and US market entry review
- Channel and partner strategy
- Commercial sequencing by region
- Cross-border expansion support
Investor and Board Support
Translate commercialization readiness, evidence, adoption risk, and timing into a clearer narrative for boards and investors.
- Commercial readiness briefs
- Investor diligence support
- Adoption, risk framing
- Commercial milestone architecture
Engagement Models
How We Engage
The right model depends on urgency, scope, and whether you need clarity, execution capacity, or capability transfer.
Sprint
Focused Review
Best for diagnostics, launch readiness, market entry review, pilot reset, or AI workflow assessment.
Embedded support
Embedded Support
Best when active workstreams need added senior execution capacity.
Build, Operate, Transfer
Build Operate Transfer
Best when capability must be built, operated, and later transferred to your team.
When We Help Best
Common reasons companies bring us in
The commercial path is not yet clear
There is a product or opportunity, but the commercial path and sequence are still unclear.
There is traction, but not enough progress
Activity is underway, but it is not converting into adoption, procurement, or revenue fast enough.
A market, segment, or geography needs to be entered properly
The company is entering Canada, the U.S., a new channel, or a new institutional environment and needs the right approach before committing resources.
Leadership needs experienced execution capacity
The work matters, but the business does not yet have the internal bandwidth or operator depth to move it forward.
Industries
Built for Regulated Health Sectors
We support sectors where regulatory progress, evidence requirements, reimbursement pathways, institutional adoption, and field execution must integrate seamlessly to create lasting commercial value.
Specialty Pharma
We provide expert support for access strategies, evidence planning, provincial sequencing, patient support program coordination, stakeholder engagement, and field execution.
- Provincial and institutional sequencing
- pCPA and HTA, aware planning
- PSP and launch coordination
- Field and account activation
Biotech
We translate scientific and regulatory progress into a practical commercialization path for teams building market capability.
- Pre, commercial planning
- Market access and evidence alignment
- Pilot and launch preparation
- Fractional commercialization leadership
Diagnostics
We sequence reimbursement logic, institutional buying pathways, account adoption, and field execution into a credible growth plan.
- Reimbursement coding and adoption planning
- Institutional contracting support
- Network and health, system targeting
- Field deployment structure
Medtech and Medical Device
Technical approval alone does not create hospital adoption. We support access planning, pilot logic, stakeholder sequencing, and contracting.
- Hospital and health, system adoption planning
- Pilot, to, procurement support
- Commercial channel and account targeting
- Launch and growth execution
AI Health
We refine positioning, redesign pilots, align stakeholder logic, and define scale criteria that convert activity into durable traction.
- Pilot redesign for adoption
- Specialist and institutional targeting
- Evidence package alignment
- Commercial readiness and growth planning
Surgical
We support surgical and procedure, based products that require hospital adoption logic, stakeholder sequencing, contracting support, and disciplined rollout.
- Hospital and surgical pathway planning
- Stakeholder and account sequencing
- Pilot, to, procurement support
- Commercial rollout execution
Proof
Evidence-Led Results
Analytics-driven, investor-grade metrics, commercialization proof points, and execution-led case examples across life sciences, diagnostics, medtech, and AI Health.
Proof
Commercial Proof and Execution Outcomes
This page brings together success stories, metrics, and supporting studies that show how Strategic Growth AI approaches commercialization.
1. How AI Agents Can Unlock Full Commercial Potential in Life Sciences
Life sciences teams must coordinate complex workflows across fragmented data, sequential decisions, and legacy systems. Agentic AI can compress that work.
Headline result: 40–50% higher operating efficiency with faster launch readiness and stronger early adoption.
2. Cut Launch Planning Time by 60%, Without Adding Headcount
After FDA approval, a specialist biotech still faced a 9-month path to commercialization because workflows were siloed and launch ownership was weak.
Headline result: launch planning completed in under 4 months, with $1.8M+ cost avoidance and first-year revenue 40–50% above forecast.
Success Stories
Selected Commercialization Stories
Examples of how execution and market judgment translated into funded adoption, scaled growth, or exit readiness.
Rare Disease · Canada
Launching a Rare Disease Company
A dormant rare disease treatment required a full Canadian medical and commercial buildout from zero infrastructure.
- Canadian operation built from the ground up
- Medical affairs, PSP, market access, and launch infrastructure established
- Top-performing affiliate outcome supporting later strategic acquisition
Digital Health · Canada
Scaling a Digital Health Platform for Acquisition
A continuing health education platform faced physician skepticism, limited adoption, and weak exit readiness.
- KOL-led credibility and content strategy implemented
- Hospital and association adoption accelerated
- Platform successfully acquired by a major healthcare education provider
Diagnostics · Canada
Disrupting a 59-Year Diagnostic Lab Monopoly
A U.S.-based lab entered a Canadian market dominated by a single incumbent and needed credibility, logistics, and compliance execution at scale.
- 1,700+ client sites secured across Canada
- Strategic partnerships drove significant revenue growth
- Client became Canada’s fastest-growing diagnostics company
Detailed Proof
Executive Summaries and Detailed Case Content
How AI Agents Can Unlock Full Commercial Potential in Life Sciences
Executive Summary
The life sciences industry is delivering unprecedented innovation, from targeted biologics and gene therapies to AI-powered diagnostics, digital therapeutics, and connected medical devices. Yet even strong innovations frequently underperform relative to their commercial and patient-impact potential. Despite deep investment and rigorous planning, 56–67% of launches fall short of pre-launch expectations, and products that miss early momentum rarely recover once adoption patterns, payer decisions, and positioning begin to harden.
This gap is usually not a talent problem. It is a structural execution problem. Biotech, medtech, diagnostics, and digital health teams are being asked to orchestrate more than 20 interdependent functions, from regulatory strategy and HTA through field operations, clinician engagement, and patient support, using disconnected data systems and sequential workflows. That forces teams to spend too much time coordinating instead of shaping outcomes.
Agentic AI offers a different operating model. By orchestrating end-to-end commercial workflows, integrating real-time intelligence across systems, and embedding compliance into the workflow, agentic AI allows experts to focus on strategy, trust, access, and decisions while technology handles orchestration.
Readiness: 4–5 months
40–50% efficiency gain
Faster early adoption
Cut Launch Planning Time by 60%, Without Adding Headcount
Executive Summary
After FDA approval of a specialist therapy, a 300+ employee biotech faced a 9-month commercialization timeline with a stretched team, siloed workflows, and no dedicated launch lead. That exposed early revenue, payer access, and launch momentum to avoidable risk.
Partnering with Strategic Growth AI, the company deployed agentic AI to automate coordination across regulatory, medical, market access, and commercial functions. Subject matter experts were then able to spend their time on strategy and decisions rather than logistics and handoffs.
- Launch planning completed in under 4 months, a 60% reduction versus the original timeline
- $1.8M+ in cost avoidance through lower FTE burden and reduced consulting spend
- First-year revenue 40–50% above forecast, with peak adoption reached 6–12 months earlier
- Zero compliance issues and 90% faster cross-functional decisions
“We went from drowning in logistics to leading with strategy. SGAI saved our launch.” — Chief Commercial Officer
Launching a Rare Disease Company
Challenge
A global pharma leader needed to launch a dormant rare disease treatment in Canada without existing local medical or commercial infrastructure.
Our Approach
Strategic Growth AI built the Canadian operation from the ground up, establishing medical affairs and patient support infrastructure, creating the market-access strategy, and executing a tailored commercial launch.
Result
Canada became the company’s top-performing global affiliate, enabling full local independence and contributing to a major strategic acquisition. This case reflects full-scale go-to-market execution in a highly specialized therapeutic area.
Scaling a Digital Health Platform for Acquisition
Challenge
A continuing health education platform struggled with physician skepticism and limited adoption, constraining growth and weakening exit potential.
Our Approach
Strategic Growth AI optimized the platform, curated high-value content from key opinion leaders, and executed targeted growth campaigns to build credibility and accelerate adoption across hospitals and associations.
Result
The platform achieved rapid user adoption and was acquired by a major healthcare education provider. The engagement demonstrates Strategic Growth AI’s ability to scale digital health ventures toward successful exits.
Disrupting a 59-Year Diagnostic Lab Monopoly
From market challenger to national presence in 18 months.
A U.S.-based diagnostics lab entered the Canadian market after decades of single-player dominance. Strategic Growth AI delivered the market-entry strategy and execution model required to convert skepticism into adoption and establish the lab as a credible alternative.
Roadblocks We Overcame
- Deep market resistance and entrenched client relationships with the incumbent provider
- Logistics complexity across a large geography with limited courier coverage
- Provincial and federal regulatory requirements
- Fast operational scaling without sacrificing quality
- A significant credibility gap against 59 years of institutional loyalty
Results Achieved
- 1,700+ client sites secured across Canada
- Significant revenue growth via strategic partnerships
- Credibility established as the first serious challenger in six decades
- Operational scalability built for long-term growth and excellence
Bottom line: the client became Canada’s fastest-growing diagnostics company, proving that focused execution can beat legacy dominance.
Investor Trusted Metrics
Investor-Grade Measurement and De-Risking
Investors now care as much about efficiency and execution risk as growth. This section shows how SGAI frames both.
Metrics We Use
- Capital efficiency metrics: Rule of 40, CAC payback, burn multiple
- Monte Carlo scenario modeling with live probability curves
- Predictable De-Risking Model across regulatory, financial, clinical, and GTM risks
- Investor-ready outputs: rNPV, IRR, MOIC, and probability of success
Why It Matters
- Regulatory-first product-market fit reduces rework and accelerates payer-backed revenue
- Payer-grade proof links HEOR, value, codes, sites of care, and price realization
- Operator execution translates strategy into paid claims, contracts, and measurable cash outcomes
- Uncertainty becomes decision-ready evidence rather than narrative optimism
What Studies Indicate
Signals Supporting Specialized Commercialization Support
Strategic Growth AI was built for healthcare and AI companies operating in regulated markets. The signals below support the case for specialized commercialization support.
ROI Potential
Analyses of specialized consulting in healthcare report meaningful positive returns, with case ranges reaching up to roughly 7:1 in select contexts. Results vary by scope, baseline, and implementation quality.
Expertise Correlates with Outcomes
Multiple studies indicate a statistically significant positive relationship between consultant specialization and project success, supporting the case for domain-specific commercialization support rather than generalist advisory work.
Generalist Risk
Public-sector analyses have reported efficiency declines when generic management-consulting approaches are used in complex healthcare settings without sufficient domain context and execution grounding.
Sources
Peer-Reviewed and Market Sources
Reference links for the studies and market sources cited on this page.
- The impact of consultants' power dynamics on clients' self-efficacy (PMC, 2025)
- Management consultancy and inefficiency in the NHS: time for an urgent review (University of Bristol policy briefing)
- Combining patient, clinical and system perspectives in assessing performance in healthcare: an integrated measurement framework (BMC Health Services Research, 2020)
- Healthcare Consulting Services Market Report 2025–2030 (Markets and Markets)
- Measuring the return from pharmaceutical innovation 2024 (Deloitte)
Unified Disclosure & Method Notes. Strategic Growth AI provides advisory services only. Evidence summaries on this page draw on peer-reviewed, governmental, and industry sources and third-party studies believed reliable but not warranted. Healthcare markets are shaped by regulatory, competitive, reimbursement, and macroeconomic change. Forward-looking statements are not guarantees of future performance. Outcomes depend on client decisions, capabilities, data quality, implementation discipline, and external factors outside Strategic Growth AI’s control. Past results and benchmarks do not guarantee future results. Any ROI figures are contextual and illustrative and will vary by organization size, complexity, implementation fidelity, and market conditions. Nothing on this page is legal, medical, tax, or investment advice.
Events
Webinars and Executive Sessions
A focused webinar series built around the commercialization decisions that most often delay adoption, funded use, and scale.
Flagship session
Approval to Adoption Risks
Regulatory clearance does not create coverage, procurement, clinical pull-through, or field readiness. This session focuses on the breakdowns that slow adoption.
Designed for regulated health teams that need a clearer path from approval to funded adoption and commercial traction.
Register Interest
Relevant to organizations considering a broader commercialization engagement.
Pilot, to, scale session
When Pilots Stall
A practical session for medtech, diagnostics, and AI Health teams whose pilots are not converting into institutional adoption, procurement, or scale.
Designed for leadership teams that need a pilot-to-scale framework grounded in evidence, stakeholder logic, and scale criteria.
Register Interest
Directly aligned to pilot reset and pilot-to-scale support.
AI workflow session
AI Workflow Enablement in Regulated Health
AI interest is high, but many teams still lack the operating model needed to deploy responsibly. This session covers workflow selection, governance design, decision rights, human oversight, and rollout priorities.
Best suited to AI Health, medtech, and diagnostics teams introducing AI into regulated commercial or regulatory workflows.
Register Interest
Designed to support serious AI adoption and governance conversations.
Need support before a session runs? Book a commercialization review and bring the launch, pilot, access, market entry, AI workflow, or governance issue that needs to move.
Book a Commercial ReviewAbout
Senior Operators With Commercial Accountability
Strategic Growth AI was built to solve a persistent challenge in regulated health: strong science and regulatory progress do not automatically create commercial adoption.
Our Model
Embedded Execution With Accountability
Strategic Growth AI helps clients decide, build, execute, and scale with senior operators working alongside the team.
We operate across Canada and the U.S. in specialty pharma, biotech, diagnostics, medtech, and AI Health.
20+ yearsCommercialization experience across regulated health markets
$300M+Commercial impact across launches and growth programs
7,000+Accounts activated in institutional and field settings
CA + USOperating footprint across both regulated markets
Contact
Discuss the commercial priority that needs to move
Use the contact page to discuss a live launch, access delay, pilot reset, cross-border expansion challenge, field execution issue, or AI workflow priority.
What to Include
Name the commercial priority that needs to move, state the stage, explain what is slowing progress, and clarify the decision or outcome that must advance next.
Typical Starting Points
Live launch support, access delays, pilot reset, cross-border expansion, field execution issues, or AI workflow priorities.
Operating Footprint
Canada and the United States, with particular strength in specialty pharma, biotech, diagnostics, medtech, AI Health.
20+
Years experience
$300M+
Commercial impact
7,000+
Accounts activated
CA+US
Operating Footprint